ArticleJournal of ovarian research2026
Upregulation of mitoNEET disrupts granulosa cell proliferation, apoptosis and mitochondrial homeostasis : a possible pathogenesis of follicular dysplasia in PCOS.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS), a leading cause of anovulatory infertility, is characterized by arrested follicular development due to imbalanced proliferation and apoptosis of granulosa cells (GCs). The molecular mechanisms of this dysfunction remain unclear. This study explores the role of mitochondrial NEET protein 1 (mitoNEET) in PCOS pathogenesis.
methodsThe expression levels of mitoNEET in GCs from PCOS patients and testosterone-treated KGN cells were analyzed using PCR and Western blot. RNA sequencing was used to probe the transcriptional changes following mitoNEET knockdown. Western blot, flow cytometry analysis, immunofluorescence imaging, and transmission electron microscopy were used to detect mitochondrial function, cell proliferation, and apoptosis in KGN cells. MitoNEET inhibitor (NL-1) was administered to a dehydroepiandrosterone (DHEA)-induced PCOS mouse model to investigate its potential therapeutic effects.
resultsWe demonstrate that mitoNEET protein and mRNA are significantly upregulated in GCs from PCOS patients, correlating with hyperandrogenism. RNA sequencing highlights its regulatory effects on mitochondrial homeostasis, cell cycle, and apoptosis. MitoNEET knockdown reversed testosterone-induced mitochondrial dysfunction, including cristae disruption, ATP depletion, mitochondrial membrane potential injurion, Mito-SOX accumulation, and aberrant dynamics (OPA1 downregulation/DRP1 upregulation), while restoring mitochondrial unfolded protein response (UPRmt) markers. Mechanistically, mitoNEET silencing activated the PI3K/AKT pathway, enhancing KGN cell proliferation (via PCNA, Cyclin B1, and CDK1) and suppressing apoptosis (Bax/Bcl-2 ratio). Pharmacological inhibition of mitoNEET with NL-1 alleviated hyperandrogenemia, restored estrous cyclicity, improved ovarian morphology, and promote ovulation in PCOS mice.
conclusionsThese findings establish mitoNEET as a pivotal mediator of mitochondrial-PI3K/AKT crosstalk in PCOS-related follicular arrest, highlighting its therapeutic potential for restoring GC function and ovarian homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.